Fetal Bovine Serum Market Size Worth USD 5.63 Billion in 2032 | Emergen Research

The global Fetal Bovine Serum (FBS) market size was USD 1.57 Billion in 2022 and is expected to register a rapid revenue CAGR of 13.7% during the forecast period. The global Fetal Bovine Serum (FBS) market is witnessing significant growth driven by increasing research activities, technological advancements, and the rising prevalence of chronic disorders. According to a recent market research report, key factors such as the development of serum-free media and cutting-edge technological advancements are shaping the trajectory of the market.

Serum-Free Media Development: One of the notable advancements in the FBS market is the development of serum-free media, offering alternatives to FBS without animal-derived components. Technologies such as dialyzed FBS, recombinant proteins, and human platelet lysate are enhancing the quality and consistency of FBS, making it more suitable for various applications including drug discovery, cell culture, and in-vitro fertilization (IVF).

To avail Sample Copy of the report @https://www.emergenresearch.com/request-sample/2818

Prevalence of Chronic Disorders: The market is further fueled by the increasing prevalence of chronic disorders worldwide, such as autoimmune and neuromuscular diseases. Unhealthy lifestyles, environmental factors, and aging populations contribute to the rise in chronic diseases, underscoring the importance of research and development in this field.

Cutting-Edge Technological Advancements: Technological advancements play a pivotal role in shaping the FBS market landscape. Companies like OMEAT have introduced innovative and sustainable alternatives to FBS, catering to a broad range of industries including cultivated meat production, regenerative medicine, and vaccine manufacturing. These advancements add value to the market by addressing ethical concerns and improving product efficacy.

Market Restraints: Despite the promising growth prospects, the high cost of FBS production remains a key restraint. The complex and labor-intensive process of extracting FBS from pregnant cows contributes to its high cost, posing challenges for market expansion.

Segment Insights:

Fetal Bovine Serum Product Types:
• Stem Cell Segment Dominance: Stem cell research drives the demand for FBS, owing to its superior performance in supporting cell proliferation, differentiation, and maintenance. While alternatives to FBS are emerging, they have yet to match its effectiveness in stem cell applications.

• Charcoal Stripped Segment Growth: Charcoal stripped FBS, known for removing impurities and contaminants, is witnessing moderate growth due to its reliability and consistency, particularly in sensitive cell lines and research involving infectious agents.

Fetal Bovine Serum Applications:

• Cell Culture Dominance: FBS remains a cornerstone in cell culture applications, facilitating research in cellular biology, drug discovery, and vaccine development. Its ability to mimic the in vivo environment is invaluable for exploring cellular functions and mechanisms.

• IVF Segment Growth: Advancements in IVF techniques and increasing awareness about infertility treatments are driving steady growth in the IVF segment. FBS provides essential nutrients for embryo development, contributing to higher success rates in IVF procedures.

Request Customization In The Report @https://www.emergenresearch.com/request-for-customization/2818

Fetal Bovine Serum End-Use:

Pharmaceutical and Biotech Dominance: Pharmaceutical and biotech companies lead in FBS adoption, investing heavily in research and development. FBS is essential for R&D activities and vaccine production, driving revenue growth in this segment.

The global Fetal Bovine Serum market is poised for significant expansion, fueled by technological innovations, rising chronic disorders, and increasing demand across various end-use industries.

Fetal Bovine Serum Top Companies and Competitive Landscape

The global FBS market is fairly fragmented, with many large and medium-sized players accounting for the majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more Fetal Bovine Serum solutions.

• Thermo Fisher Scientific Inc.
• Danaher
• Bio-Techne
• Merck KGaA
• HiMedia Laboratories.
• Panacea Biotec
• GE Healthcare
• TCS Biosciences Ltd
• Tissue Culture Biologicals
• ROCKY MOUNTAIN BIOLOGICALS

Fetal Bovine Serum Latest Industry News

• On 8 December 2021, Thermo Fisher Scientific Inc. announced to acquire PPD, Inc. This acquisition enables Thermo Fisher to provide a comprehensive range of services throughout the entire drug development process, starting with scientific research and ending with the production of the final drug product. Thermo Fisher's services now include safety and efficacy assessments, clinical trial management, and drug development and manufacturing.

• On 1 September 2021, BioLife Solutions announced the acquisition of Sexton Biotechnologies. Sexton's expertise in bio production tools includes proprietary closed vials for cell therapy final dose packaging, Human Platelet Lysate (HPL) media, a bio-defined alternative to fetal bovine serum or human serum for cell manufacturing, and automated cell processing machines. These innovative products are currently being used in over 50 clinical trials for new cell and gene therapies.

Browse The Full Fetal Bovine Serum Market Report Description, Along With The Tocs And List Of Facts And Figures @ https://www.emergenresearch.com/industry-report/fetal-bovine-serum-market

Fetal Bovine Serum Market Segment Analysis

For the purpose of this report, Emergen Research has segmented the global FBS market on the basis of product type, application, end-use, and region:

• Product Type Outlook (Revenue, USD Billion; 2019-2032)
o Charcoal Stripped
o Exosome Depleted
o Stem Cell
o Others

• Application Outlook (Revenue, USD Billion; 2019-2032)
o Cell Culture
o Drug Discovery
o IVF
o Others

• End-Use Outlook (Revenue, USD Billion; 2019-2032)
o Pharmaceutical and Biotechnology Companies
o Contract Research Organization
o Research Institute

• Regional Outlook (Revenue, USD Billion; 2019-2032)
o North America
1. U.S.
2. Canada
3. Mexico
o Europe
1. Germany
2. France
3. UK
4. Italy
5. Spain
6. Benelux
7. Rest of Europe
o Asia Pacific
1. China
2. India
3. Japan
4. South Korea
5. Rest of APAC
o Latin America
1. Brazil
2. Rest of LATAM
o Middle East & Africa
1. Saudi Arabia
2. UAE
3. South Africa
4. Turkey
5. Rest of Middle East & Africa

Click Here To Buy Now @https://www.emergenresearch.com/select-license/2818

Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.

This release was published on openPR.